Ketamine for Treatment-Resistant Depression: Clinical Practice and Policy in the US
Growing off-label use of ketamine for treatment-resistant depression (TRD) prompts new clinical guidance, policy questions, and safety considerations for US practitioners.
Ketamine’s Expanding Role in Treatment-Resistant Depression
Clinical interest in ketamine for treatment-resistant depression (TRD) continues to rise in the United States, as reflected by recent coverage in Psychiatric Times and growing demand among prescribers and patients. Ketamine, originally approved by the US Food and Drug Administration (FDA) as an anesthetic, has seen increasing off-label use in psychiatric settings for individuals who do not respond to conventional antidepressants. This trend is driven by both emerging clinical evidence and the pressing need for effective interventions in TRD, a condition affecting up to 30% of patients with major depressive disorder.
While esketamine (the S-enantiomer of ketamine) received FDA approval for TRD in 2019 under the brand name Spravato, generic racemic ketamine remains unapproved for psychiatric indications but is widely used in outpatient clinics. The distinction between these formulations is not merely regulatory—differences in administration, dosing, and monitoring requirements have practical implications for clinical practice.
Mechanism of Action and Clinical Rationale
Ketamine’s antidepressant effects are believed to stem from its antagonism of the N-methyl-D-aspartate (NMDA) receptor, leading to increased glutamate signaling and downstream neuroplastic changes. Unlike traditional selective serotonin reuptake inhibitors (SSRIs), which may take weeks to achieve full effect, ketamine can produce rapid—sometimes within hours—improvements in depressive symptoms, including suicidality. This rapid onset is particularly relevant for acutely suicidal or severely ill patients, though the durability of benefit remains a subject of ongoing research.
Recent randomized controlled trials (RCTs), such as those registered under NCT02418585 and NCT03113968, have demonstrated statistically significant reductions in depressive symptoms with intravenous (IV) ketamine compared to placebo. However, heterogeneity in dosing protocols, patient selection, and outcome measures complicates direct comparison across studies and limits generalizability to routine practice.
Regulatory and Policy Landscape
Ketamine’s use for TRD in the US remains off-label, except for esketamine, which is subject to a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA. The REMS program requires administration in certified healthcare settings and post-dose monitoring for at least two hours, reflecting concerns about dissociation and abuse potential. In contrast, off-label IV or intranasal ketamine is often administered in outpatient clinics with variable oversight, raising questions about standardization and patient safety.
While the Drug Enforcement Administration (DEA) classifies ketamine as a Schedule III controlled substance, there is currently no federal prohibition on its off-label psychiatric use. However, some state medical boards have issued guidance or warnings regarding ketamine clinics, especially in response to reports of adverse events or questionable marketing practices. Notably, insurance coverage for off-label ketamine remains inconsistent, creating financial barriers for many patients and influencing the growth of cash-pay clinics.
Risks, Unknowns, and Clinical Caveats
Ketamine’s safety profile in psychiatric use is not fully characterized, with known risks including dissociation, elevated blood pressure, and potential for misuse or dependence. Long-term safety data are limited, particularly regarding repeated dosing and neurocognitive effects. Adverse events, such as those reported in post-marketing surveillance and case series, underscore the need for careful patient selection and monitoring.
There is also uncertainty regarding optimal dosing frequency, maintenance strategies, and the comparative effectiveness of ketamine versus esketamine. A non-obvious challenge is the lack of standardized protocols for integrating ketamine with psychotherapy, despite anecdotal reports that adjunctive therapy may enhance outcomes. This gap in evidence-based guidance leaves clinicians to navigate a landscape of evolving best practices with limited consensus.
Outlook: Research, Policy, and Practice Implications
Ongoing clinical trials and real-world studies are expected to clarify ketamine’s role in TRD, including its long-term efficacy, safety, and optimal use parameters. The increasing visibility of ketamine in both academic and mainstream psychiatric discourse may influence future policy decisions, such as expanded insurance coverage or the development of formal clinical guidelines by professional organizations.
For researchers, the current environment highlights the need for pragmatic trials and registries capturing diverse patient populations and real-world outcomes. For policymakers, the proliferation of ketamine clinics raises regulatory questions about quality assurance, patient safety, and equitable access. Clinicians must balance the promise of rapid symptom relief with the responsibility to mitigate risks and set realistic expectations for patients. As the field evolves, lessons from ketamine’s trajectory may inform the integration of other novel or psychedelic therapies into mental health care.
By Dr. Alex Morgan, MD, PhD. Reviewed by Dr. Jamie Lee, MD on 2026-11-18. Sources: FDA Spravato REMS, NCT02418585, NCT03113968.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.